InnoGene Co

InnoGene Co Net Debt

The Net Debt of InnoGene Co (344860.KQ) as of Oct 18, 2026 is -13.27 B KRW. In the previous year, Net Debt was -12.93 B KRW — a change of 2.61% (lower).

Net Debt

-13.27 BKRW

YoY

2.61%

Last updated:

Net Debt of InnoGene Co is 2024 -13.27 B KRW. Net Debt of InnoGene Co was 2023 -12.93 B KRW. It decreases by 2.61% lower compared to the previous year.

The InnoGene Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
391.20 M KRW
Jan 1, 2019
255.40 M KRW
Jan 1, 2020
-547.10 M KRW
Jan 1, 2021
-2.65 B KRW
Jan 1, 2022
-3.04 B KRW
Jan 1, 2023
-12.93 B KRW
Jan 1, 2024
-13.27 B KRW
The InnoGene Co Net Debt history
YEARNet DebtYoY
-13.27 BKRW+2.61%
-12.93 BKRW+325.55%
-3.04 BKRW+14.78%
-2.65 BKRW+383.92%
-547.10 MKRW-314.21%
255.40 MKRW-34.71%
391.20 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InnoGene Co Stock analysis

What does InnoGene Co do? InnoGene Co Ltd is a company based in Seoul, South Korea, operating within the Consumer Staples sector and the Consumer products industry. The company has 77 employees and went public on April 27, 2020. Its website is http://www.innogene.com/. InnoGene focuses on research and development related to skin regeneration and anti-aging solutions, utilizing stem cell technology and fusion technology. The company develops and manufactures cosmetics aimed at skin regeneration and aging control. Additionally, InnoGene is involved in the manufacturing and distribution of medical devices. The company's primary activities revolve around creating products that address skin health and aging concerns, leveraging scientific research in stem cell applications. As a publicly traded entity, InnoGene operates under the ticker symbol 344860.KQ and is registered with the ISIN KR7344860002. The company's headquarters are located in Seoul, and it serves a market that values innovative skincare and medical device solutions. InnoGene's product portfolio includes both cosmetic and medical device offerings, targeting consumers interested in advanced skincare technologies. The company's operations are centered on research-driven development to enhance skin health and combat aging effects. InnoGene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InnoGene Co stock

Net Debt of InnoGene Co is -13.27 B KRW in 2024.

Net Debt of InnoGene Co changed from -12.93 B KRW to -13.27 B KRW, representing a 2.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt InnoGene Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's InnoGene Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — InnoGene Co

All Key Metrics — InnoGene Co